Redwood City, United States
Adicet Bio, Inc, a leading innovator in the biopharma and biotechnology sectors, focuses on discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies to combat cancer and autoimmune diseases. Founded in 2014 and headquartered in the United States, Adicet prides itself on its pioneering role in the cell therapy space.
With a clear mission to provide readily available off-the-shelf therapies by leveraging gamma-delta T cells that target cancer cells and facilitate immune reset in autoimmune diseases, Adicet stands out in its ability to innovate and execute. The company's recent $80.00M post-IPO equity investment on October 1, 2025, underscores strong investor confidence in its promising pipeline.
Stakeholders value Adicet for its robust culture and talented team, continuously driving transformational therapies and maintaining a strong employee-focused environment, making it an attractive proposition for future investments.
